These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33704192)

  • 1. Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
    Fingrut W; Davis W; McGinnis E; Dallas K; Ramadan K; Merkeley H; Leitch H; Abou Mourad Y; Cassaday RD; Ross C; Léger C
    Curr Oncol; 2020 Dec; 28(1):252-259. PubMed ID: 33704192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A; O'Brien SM
    Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J; Marx K; Jabbour E
    Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotuzumab Ozogamicin: First Pediatric Approval.
    Dhillon S
    Paediatr Drugs; 2024 Jul; 26(4):459-467. PubMed ID: 38780741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
    Kantarjian HM; Su Y; Jabbour EJ; Bhattacharyya H; Yan E; Cappelleri JC; Marks DI
    Cancer; 2018 May; 124(10):2151-2160. PubMed ID: 29508899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of CD22 expression and expansion of a CD22
    Reinert J; Beitzen-Heineke A; Wethmar K; Stelljes M; Fiedler W; Schwartz S
    Ann Hematol; 2021 Nov; 100(11):2727-2732. PubMed ID: 34331563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN
    Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Nakayama H; Ogawa C; Sekimizu M; Fujisaki H; Kosaka Y; Hashimoto H; Saito AM; Horibe K
    Int J Hematol; 2022 Oct; 116(4):612-621. PubMed ID: 35635686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
    Rubinstein JD; O'Brien MM
    Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
    Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
    Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
    Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
    Wynne J; Wright D; Stock W
    Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    Yurkiewicz IR; Muffly L; Liedtke M
    Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
    George B; Kantarjian H; Jabbour E; Jain N
    Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
    Paul MR; Wong V; Aristizabal P; Kuo DJ
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
    Zhao Y; Short NJ; Kantarjian HM; Chang TC; Ghate PS; Qu C; Macaron W; Jain N; Thakral B; Phillips AH; Khoury J; Garcia-Manero G; Zhang W; Fan Y; Yang H; Garris RS; Nasr LF; Kriwacki RW; Roberts KG; Konopleva M; Jabbour EJ; Mullighan CG
    Blood; 2024 Jul; 144(1):61-73. PubMed ID: 38551807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
    Kantarjian H; Thomas D; Jorgensen J; Jabbour E; Kebriaei P; Rytting M; York S; Ravandi F; Kwari M; Faderl S; Rios MB; Cortes J; Fayad L; Tarnai R; Wang SA; Champlin R; Advani A; O'Brien S
    Lancet Oncol; 2012 Apr; 13(4):403-11. PubMed ID: 22357140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
    de Vries JF; Zwaan CM; De Bie M; Voerman JS; den Boer ML; van Dongen JJ; van der Velden VH
    Leukemia; 2012 Feb; 26(2):255-64. PubMed ID: 21869836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.